Last updated: February 15, 2026
Overview
NDC 33342-0384 corresponds to Abecma (idecabtagene vicleucel), a CAR-T cell therapy developed by Bristol-Myers Squibb (BMS) and discussed within the context of the multiple myeloma treatment landscape. Approved by the U.S. Food and Drug Administration (FDA) in March 2021 for relapsed or refractory multiple myeloma in adults, it represents a significant advancement in personalized immunotherapy. The following analysis details current market conditions and forecasts future pricing trends.
Market landscape
-
Indication and Competitors
-
Approved for relapsed/refractory multiple myeloma (RRMM) following four or more prior lines of therapy.
-
Competitors include carfilzomib, daratumumab + pomalidomide + dexamethasone, idecabtagene vicleucel (NDC 33342-0384), and ciltacabtagene autoleucel (Lunar-4).
-
Market size: Approximate annual incidence of multiple myeloma in the U.S. is 35,000 new cases; patients with relapsed/refractory disease cumulatively number over 100,000, expanding as new treatments emerge.
-
Adoption Rates
-
As of Q2 2023, BMS reports increased utilization, with around 2,000 to 3,000 patients treated globally.
-
Access barriers include manufacturing complexity, infrastructure for cell therapy administration, and payer reimbursement policies.
-
Pricing and Reimbursement
-
List price: FDA-approved pricing is approximately $419,500 per treatment (per BMS filing, March 2021).
-
Payer negotiations often reduce net prices. Commercial payers employ risk-sharing arrangements, sometimes lowering effective costs by 10–20%.
-
Cost components include manufacturing, infusion, hospitalization, and post-treatment management.
Price projections
-
Current Price Points
-
List Price: ~$420,000 per therapy course.
-
Net Price: Estimated at $336,000–$378,000 after rebates, discounts, or risk-sharing agreements.
-
Factors influencing future pricing
-
Market penetration: Increased adoption due to expanding indications may exert downward pressure, especially as biosimilar or next-generation therapies emerge.
-
Manufacturing costs: Advances in process efficiencies may reduce costs by 10–15% over the next 2–3 years.
-
Competitive landscape: Introduction of newer CAR-T therapies and combination regimens could lead to pricing compression to maintain market share.
-
Payer policies: Push for value-based pricing and outcomes-based reimbursement could alter payment structures, impacting net prices.
-
Forecasted pricing trends (2023–2028)
| Year |
Estimated List Price |
Expected Net Price Range |
Drivers |
| 2023 |
$420,000 |
$336,000–$378,000 |
Market stabilization, initial access hurdles |
| 2024 |
$410,000 |
$328,000–$370,000 |
Early competition, cost reductions |
| 2025 |
$400,000 |
$320,000–$360,000 |
New entrants, value-based models |
| 2026 |
$390,000 |
$312,000–$351,000 |
Patent protections, market maturity |
| 2027 |
$385,000 |
$308,000–$350,000 |
Generics or biosimilar considerations |
| 2028 |
$380,000 |
$304,000–$342,000 |
Further manufacturing efficiencies |
Impacts of regulatory and policy shifts
-
Pricing pressure: CMS and private insurers increasingly favor value-based agreements for high-cost therapies like CAR-T. This could compress prices further and shift from list to net prices.
-
Cell therapy approvals: New indications, partly driven by clinical trial data, might expand the patient population but could also lead to price negotiations to ensure broad access.
-
Manufacturing innovations: Automation and centralized manufacturing could reduce costs, enabling price discounts while maintaining margins.
Conclusion
The current market for NDC 33342-0384 centers around about $420,000 list price per treatment, with net prices possibly 20–25% lower. Market growth hinges on expanded indications, access infrastructure, and competitive entries. Price declines of 2–3% annually are projected primarily due to increased competition, manufacturing efficiencies, and evolving reimbursement policies. The overall trend indicates stable high pricing through 2028, albeit with gradual downward pressure.
Key Takeaways
- Market size for relapsed/refractory multiple myeloma favors continued growth in CAR-T therapy adoption.
- Pricing models are shifting towards value-based agreements, influencing net prices.
- Cost reductions from manufacturing efficiencies may lower prices gradually.
- Competitive landscape consists of emerging therapies and biosimilars, likely compressing prices after 2025.
- Regulatory and policy environment is a critical factor influencing future reimbursement structures and pricing.
FAQs
1. How does the pricing of NDC 33342-0384 compare to other CAR-T therapies?
It is comparable to ciltacabtagene autoleucel (around $425,000 list price), with some variation based on indications and payer negotiations. Other CAR-Ts like tisagenlecleucel (Kymriah) have similar pricing models but target different indications.
2. What are the main cost drivers for this therapy besides the drug itself?
Cost drivers include manufacturing expenses, hospitalization during infusion, lymphodepleting chemotherapy, and post-treatment management for adverse events.
3. Will biosimilars or alternative therapies significantly reduce prices?
Biosimilars for CAR-T therapies are unlikely in the near term due to manufacturing complexity. However, next-generation therapies could exert downward pressure after 2025.
4. How are payers influencing future pricing?
Payers incentivize outcomes-based reimbursement models, which may lead to discounts or annuity-based payments linked to patient response and durability.
5. What factors could cause the price to increase instead of decrease?
Limited competition, high demand, or regulatory barriers delaying biosimilar introduction could sustain or increase prices for several years.
References
[1] Bristol-Myers Squibb. Abecma (idecabtagene vicleucel) prescribing information. March 2021.
[2] IQVIA. Market Reports on Multiple Myeloma Treatments, 2023.
[3] FDA. Approval announcements for CAR-T therapies, 2021–2023.
[4] CMS and private payers’ reimbursement policies, 2023.
